Chembio Diagnostics, Inc. (NasdaqCM: CEMI)

About Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc., along with its subsidiaries, specializes in creating, producing, and bringing to market point-of-care (POC) diagnostic tests used for identifying and diagnosing various diseases. Their current product offerings include tests for critical conditions like COVID-19, HIV/Syphilis, and the Zika virus. Beyond these, the company is dedicated to advancing diagnostics for a wide array of other infectious diseases, such as malaria, dengue, chikungunya, Chagas disease, Ebola, leishmaniasis, Lassa fever, Marburg virus, leptospirosis, rickettsia, and Burkholderia infections. These diagnostic tools are sold under well-known brand names including STAT-PAK, SURE CHECK, STAT VIEW, and DPP. Chembio distributes its products directly and through various partners to a diverse global customer base. This clientele includes medical laboratories, hospitals, government and public health agencies, non-governmental organizations (NGOs), medical professionals, and retail outlets across the United States and worldwide. The company engages in strategic partnerships with prominent organizations such as the Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics. Additionally, Chembio collaborates with several key U.S. government entities, including the Centers for Disease Control and Prevention (CDC), the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture (USDA). Founded in 1985, Chembio Diagnostics, Inc. has its headquarters located in Hauppauge, New York.

ISIN

US1635722093

Founded

1985

Listed since

Oct 18, 2000

Exchange

Nasdaq Capital Market

Currency

USD